MA53400A - Hétéromultimères alk7: actriib et leurs utilisations - Google Patents

Hétéromultimères alk7: actriib et leurs utilisations

Info

Publication number: MA53400A
Authority: MA; Morocco
Prior art keywords: actriib; alk7 heteromultimers; alk7; heteromultimers
Prior art date: 2015-04-06

Application number

MA053400A

Other languages

English (en)

Inventor

Roselyne Castonguay

Yossi Dagon

Asya Grinberg

John Knopf

Ravindra Kumar

Gang Li

Robert Scott Pearsall

Dianne S Sako

Original Assignee

Acceleron Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-06

Filing date

2016-04-06

Publication date

2021-08-04

2016-04-06 Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc

2021-08-04 Publication of MA53400A publication Critical patent/MA53400A/fr

Links

102100034135 Activin receptor type-1C Human genes 0.000 title 1
101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 title 1
101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)

MA053400A 2015-04-06 2016-04-06 Hétéromultimères alk7: actriib et leurs utilisations MA53400A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562143579P	2015-04-06	2015-04-06

Publications (1)

Publication Number	Publication Date
MA53400A true MA53400A (fr)	2021-08-04

Family

ID=57072866

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
MA41920A MA41920B1 (fr)	2015-04-06	2016-04-06	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA054328A MA54328A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA053400A MA53400A (fr)	2015-04-06	2016-04-06	Hétéromultimères alk7: actriib et leurs utilisations
MA041916A MA41916A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
MA41920A MA41920B1 (fr)	2015-04-06	2016-04-06	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA054328A MA54328A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA041916A MA41916A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Country Status (15)

Country	Link
US (7)	US10227392B2 (fr)
EP (5)	EP3889171B1 (fr)
JP (3)	JP7055636B2 (fr)
KR (2)	KR20180002661A (fr)
CN (4)	CN107847561B (fr)
AU (4)	AU2016246708B2 (fr)
BR (1)	BR112017021510A2 (fr)
CA (2)	CA2981833A1 (fr)
DK (1)	DK3280728T3 (fr)
EA (2)	EA202190016A1 (fr)
ES (2)	ES2863564T3 (fr)
HK (2)	HK1252957A1 (fr)
MA (4)	MA41920B1 (fr)
MX (1)	MX391964B (fr)
WO (2)	WO2016164503A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HK1225740A1 (zh)	2013-08-22	2017-09-15	Acceleron Pharma Inc.	TGF-β受体II型变体及其用途
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
MA41920B1 (fr)	2015-04-06	2021-05-31	Acceleron Pharma Inc	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
US10358476B2 (en)	2015-04-06	2019-07-23	Acceleron Pharma Inc.	Single arm type I and type II receptor fusion proteins and uses thereof
CA2983440C (fr)	2015-04-22	2024-03-12	Alivegen Usa Inc.	Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques
CN108348578B (zh)	2015-08-04	2022-08-09	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
CN105254764A (zh) *	2015-08-27	2016-01-20	上海康岱生物医药技术有限公司	ACVR1-Fc融合蛋白及其制法和用途
WO2017177013A1 (fr)	2016-04-06	2017-10-12	Acceleron Pharma Inc.	Antagonistes d'alk7 et leurs utilisations
DK3496739T3 (da)	2016-07-15	2021-05-10	Acceleron Pharma Inc	Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
AU2017338915B2 (en) *	2016-10-05	2024-11-21	Acceleron Pharma Inc.	TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
CA3039573A1 (fr)	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Heteromultimeres alk4:actriib et leurs utilisations
CN110036025B (zh)	2016-10-05	2024-03-22	阿塞勒隆制药公司	变体ActRIIB蛋白及其用途
CA3039074A1 (fr) *	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Compositions et methode pour le traitement de la renopathie
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
NZ754161A (en)	2016-11-10	2025-11-28	Keros Therapeutics Inc	Activin receptor type iia variants and methods of use thereof
MA46862A (fr)	2016-11-17	2019-09-25	Bluebird Bio Inc	Convertisseur de signaux tgf béta
EP3576773B1 (fr) *	2017-02-01	2023-10-18	Acceleron Pharma Inc.	Antagonistes du tgf beta et d'actrii à utiliser dans le traitement de la leucémie
ES2948647T3 (es)	2017-05-04	2023-09-15	Acceleron Pharma Inc	Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
EP3424957A1 (fr) *	2017-07-03	2019-01-09	advanceCOR GmbH	Protéine de fusion
AU2018358804A1 (en) *	2017-11-02	2020-04-09	Bayer Aktiengesellschaft	Bispecific antibodies binding ALK-1 and BMPR-2
IL320014A (en)	2018-01-12	2025-06-01	Keros Therapeutics Inc	Activin receptor type iib variants and methods of use thereof
JP7654402B2 (ja) *	2018-02-09	2025-04-01	アクセルロンファーマインコーポレイテッド	異所性骨化を処置するための方法
MX2020009272A (es) *	2018-03-06	2021-01-08	Univ Pennsylvania	Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
US12168683B2 (en)	2018-05-03	2024-12-17	Acceleron Pharma Inc.	Binders of TGFβ-superfamily ligands and uses thereof
US12103959B2 (en)	2018-05-03	2024-10-01	Acceleron Pharma Inc.	Multispecific binders of TGFBeta-superfamily ligands and uses thereof
KR20250133994A (ko) *	2018-05-09	2025-09-09	케로스 테라퓨틱스, 인크.	액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
WO2019226658A1 (fr)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
CA3099308A1 (fr)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions et procedes pour ameliorer la destruction de cellules cibles par des lymphocytes nk
CA3103427A1 (fr) *	2018-06-15	2019-12-19	Acceleron Pharma Inc.	Proteines de fusion bi- et tri-fonctionnelles et utilisations associees
CA3139011A1 (fr)	2019-05-08	2020-11-12	Medigene Immunotherapies Gmbh	Lymphocytes t genetiquement modifies
US20220362333A1 (en) *	2019-07-26	2022-11-17	Board Of Trustees Of Michigan State University	Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
CN112625137B (zh) *	2019-10-08	2021-10-08	北京东方百泰生物科技股份有限公司	一种人白细胞介素10-Fc融合蛋白及其医药用途
MX2022009553A (es) *	2020-02-03	2022-11-07	Acceleron Pharma Inc	Proteínas actriib variantes y sus usos.
AU2021236249A1 (en) *	2020-03-13	2022-10-06	Acceleron Pharma Inc.	Single-arm ActRIIA and ActRIIB heteromultimers and methods for treating renal diseases or conditions
WO2021189010A1 (fr)	2020-03-20	2021-09-23	Keros Therapeutics, Inc.	Procédés d'utilisation de variants de récepteur de l'activine de type iib
WO2021189019A1 (fr) *	2020-03-20	2021-09-23	Keros Therapeutics, Inc.	Chimères de type ii du récepteur d'activine et leurs méthodes d'utilisation
US20230174620A1 (en)	2020-04-28	2023-06-08	Acceleron Pharma Inc.	Actrii proteins and use in treating post-capillary pulmonary hypertension
KR102587871B1 (ko) *	2020-06-19	2023-10-12	숙명여자대학교산학협력단	Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도
CA3196443A1 (fr) *	2020-11-04	2022-05-12	Hq Han	Nouveaux antagonistes multispecifiques bifonctionnels capables d'inhiber de multiples ligands de la famille du tgf-beta et utilisations correspondantes
WO2022192411A1 (fr) *	2021-03-10	2022-09-15	Acceleron Pharma Inc.	Antagonistes de l'actrii-alk4 et méthodes de traitement de l'insuffisance cardiaque
JP2024511315A (ja) *	2021-03-10	2024-03-13	アクセルロンファーマインコーポレイテッド	Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法
EP4673472A1 (fr) *	2023-03-01	2026-01-07	The Regents of University of California	Utilisation d'inhibiteurs alk1 du récepteur bmp dans des thérapies contre l'arthrose
WO2025034616A1 (fr) *	2023-08-04	2025-02-13	Lask Pharma, Inc.	Protéines de type 1b du récepteur de protéine morphogénétique osseuse soluble (bmp) et leurs utilisations
WO2025137384A1 (fr) *	2023-12-20	2025-06-26	Arrowhead Pharmaceuticals, Inc.	Procédés et réactifs pour une synthèse améliorée d'oligonucléotides

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5955A (en)		1848-12-05		Plate for boiler-holes in cooking-stoves
DE3382562D1 (de)	1982-09-24	1992-06-25	Us Health	Wiederherstellung von gewebe bei tieren.
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0368684B2 (fr)	1988-11-11	2004-09-29	Medical Research Council	Clonage de séquences d'immunoglobulines de domaines variables.
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5580737A (en)	1990-06-11	1996-12-03	Nexstar Pharmaceuticals, Inc.	High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
ES2259800T3 (es)	1990-06-11	2006-10-16	Gilead Sciences, Inc.	Procedimientos de uso de ligandos de acido nucleico.
US5707796A (en)	1990-06-11	1998-01-13	Nexstar Pharmaceuticals, Inc.	Method for selecting nucleic acids on the basis of structure
US5763177A (en)	1990-06-11	1998-06-09	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5567588A (en)	1990-06-11	1996-10-22	University Research Corporation	Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (fr)	1990-12-03	2003-02-04	Lisa J. Garrard	Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US20050186593A1 (en) *	1991-05-10	2005-08-25	The Salk Institute For Biological Studies	Cloning and recombinant production of CRF receptor(s)
EP1400536A1 (fr)	1991-06-14	2004-03-24	Genentech Inc.	Procédé pour fabriquer des anticorps humanisés
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
FI941572A7 (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (fr)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions induisant la destruction de cellules infectees par l'hiv
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
CA2372813A1 (fr)	1992-02-06	1993-08-19	L.L. Houston	Proteine fixatrice biosynthetique pour marqueur du cancer
CA2149441C (fr)	1992-11-17	2004-03-02	Kohei Miyazono	Kinases apparentees au recepteur de l'activine, proteines a domaines de serine threonine kinase et leur utilisation
US7592428B1 (en)	1992-11-17	2009-09-22	Ludwig Institute For Cancer Research	Antibodies which bind specifically to activin receptor like kinases
US5677196A (en)	1993-05-18	1997-10-14	University Of Utah Research Foundation	Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en)	1994-03-29	1996-06-11	Onyx Pharmaceuticals, Inc.	Reverse two-hybrid method
US5614609A (en)	1994-10-20	1997-03-25	Carlos F. Ibanez	Serine threonine kinase receptor
US5814565A (en)	1995-02-23	1998-09-29	University Of Utah Research Foundation	Integrated optic waveguide immunosensor
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
NZ306767A (en)	1995-04-11	2000-03-27	Univ Johns Hopkins	Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6699843B2 (en)	1995-06-07	2004-03-02	Gilead Sciences, Inc.	Method for treatment of tumors using nucleic acid ligands to PDGF
JPH10303327A (ja)	1997-04-23	1998-11-13	Yamaichi Electron Co Ltd	半導体チップの接点変換構造と該接点変換構造を有する半導体チップの製造法
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US6011577A (en)	1997-06-30	2000-01-04	Polaroid Corporation	Modular optical print head assembly
JP2001513982A (ja)	1997-08-29	2001-09-11	ヒューマンジノームサイエンシーズ，インコーポレイテッド	フォリスタチン−３
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
DK1034298T3 (da)	1997-12-05	2012-01-30	Scripps Research Inst	Humanisering af murint antistof
US6335155B1 (en)	1998-06-26	2002-01-01	Sunesis Pharmaceuticals, Inc.	Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
CA2355215A1 (fr)	1998-12-28	2000-07-06	Jim Wells	Identification de ligands de type petites molecules organiques, destines a former des liaisons
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
MXPA01007366A (es)	1999-01-21	2002-06-04	Metamorphix Inc	Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
DE60042021D1 (de)	1999-07-29	2009-05-28	Gilead Sciences Inc	Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
EP1240319A1 (fr)	1999-12-15	2002-09-18	Genentech, Inc.	Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
JP2003531588A (ja)	2000-04-11	2003-10-28	ジェネンテック・インコーポレーテッド	多価抗体とその用途
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CA2430013C (fr)	2000-11-30	2011-11-22	Medarex, Inc.	Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
CA2488441C (fr)	2002-06-03	2015-01-27	Genentech, Inc.	Bibliotheques de phages et anticorps synthetiques
US20040223966A1 (en)	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
WO2004065416A2 (fr)	2003-01-16	2004-08-05	Genentech, Inc.	Banques de phages anticorps synthetiques
DK1670511T3 (da)	2003-09-15	2009-11-23	Res Dev Foundation	Cripto-antagonisme af activin- og TGF-B-signalering
WO2005025601A1 (fr)	2003-09-15	2005-03-24	Monash University	Isoformes de follistatine et leurs utilisations
EP3006039B1 (fr) *	2004-03-02	2021-01-06	Acceleron Pharma Inc.	Alk7 polypeptides pour stimuler la perte de graisse
EP1740615B1 (fr)	2004-03-31	2014-11-05	Genentech, Inc.	Anticorps anti-tgf-beta humanises
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PT1737891E (pt)	2004-04-13	2013-04-16	Hoffmann La Roche	Anticorpos anti p-selectina
JP2008507288A (ja)	2004-07-23	2008-03-13	アクセルロンファーマインコーポレーテッド	ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
DK1791565T3 (en)	2004-09-23	2016-08-01	Genentech Inc	Cysteingensplejsede antibodies and conjugates
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
SI1973559T1 (sl) *	2005-11-23	2013-05-31	Acceleron Pharma, Inc.	Aktivin-aktriia antagonisti in uporaba za pospeĺ evanje kostne rasti
ES2649983T3 (es)	2005-11-23	2018-01-16	Acceleron Pharma, Inc.	Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
EP1973951A2 (fr)	2005-12-02	2008-10-01	Genentech, Inc.	Polypeptides de liaison avec des sequences de diversite limitees
TW200812616A (en)	2006-05-09	2008-03-16	Genentech Inc	Binding polypeptides with optimized scaffolds
EP2024386A2 (fr) *	2006-06-02	2009-02-18	Wyeth	Utilisation de protéines et de peptides de la superfamille tgf-bêta pour des procédés de purification et de thérapie
JP2009541275A (ja)	2006-06-22	2009-11-26	ノボ・ノルデイスク・エー／エス	二重特異性抗体の生産
WO2008030367A2 (fr)	2006-09-01	2008-03-13	The General Hospital Corporation	Inhibiteurs sélectifs de la myostatine
CN111518218A (zh) *	2006-11-02	2020-08-11	阿塞勒隆制药公司	Alk1受体和配体拮抗剂及其用途
CA2671983A1 (fr)	2006-12-08	2009-06-19	Acceleron Pharma Inc.	Utilisations de cerberus, de coco et de leurs derives
CN104524548A (zh) *	2006-12-18	2015-04-22	阿塞勒隆制药公司	活化素-actrii拮抗剂及在提高红细胞水平中的用途
TW201803890A (zh) *	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
US7947646B2 (en)	2007-03-06	2011-05-24	Amgen Inc.	Variant activin receptor polypeptides
ES2449753T3 (es)	2007-03-19	2014-03-21	National Research Council Of Canada	Proteínas de fusión que comprenden dos dominios de unión tgf-beta
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
JP6157046B2 (ja)	2008-01-07	2017-07-05	アムジェンインコーポレイテッド	静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
JP5719766B2 (ja) *	2008-05-02	2015-05-20	アクセルロンファーマ，インコーポレイテッド	血管新生および周皮細胞組成物を調節するための方法および組成物
TW201803586A (zh)	2008-08-14	2018-02-01	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
EP2326670A4 (fr)	2008-09-17	2014-04-16	Nat Res Council Canada	Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf-
JP5611222B2 (ja)	2008-11-26	2014-10-22	アムジエン・インコーポレーテツド	アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
AU2010204985A1 (en)	2009-01-13	2011-08-04	Acceleron Pharma Inc.	Methods for increasing adiponectin
JP5755635B2 (ja)	2009-03-30	2015-07-29	アクセルロンファーマ，インコーポレイテッド	Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
KR20180026795A (ko)	2009-06-12	2018-03-13	악셀레론 파마 인코포레이티드	절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP2478013B1 (fr)	2009-09-16	2018-10-24	F.Hoffmann-La Roche Ag	Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
FR2951408B1 (fr)	2009-10-15	2012-01-13	Renault Sa	Cadre moteur pour moteur electrique de vehicule automobile
AR080794A1 (es)	2010-03-26	2012-05-09	Hoffmann La Roche	Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012027065A2 (fr)	2010-08-27	2012-03-01	Celgene Corporation	Polythérapie pour traiter des maladies
CN102850458B (zh)	2011-06-28	2014-10-01	华博生物医药技术（上海）有限公司	新型重组双功能融合蛋白及其制法和用途
WO2013063536A1 (fr)	2011-10-27	2013-05-02	Acceleron Pharma, Inc.	AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI
WO2013149094A1 (fr)	2012-03-28	2013-10-03	The Board Of Regents Of The University Of Texas System	Fusions du récepteur de tgfβ de type ii-type iii
HK1225740A1 (zh)	2013-08-22	2017-09-15	Acceleron Pharma Inc.	TGF-β受体II型变体及其用途
WO2016090035A2 (fr)	2014-12-02	2016-06-09	La Jolla Institute For Allergy And Immunology	Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
US10358476B2 (en)	2015-04-06	2019-07-23	Acceleron Pharma Inc.	Single arm type I and type II receptor fusion proteins and uses thereof
MA41920B1 (fr)	2015-04-06	2021-05-31	Acceleron Pharma Inc	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
CA2983440C (fr)	2015-04-22	2024-03-12	Alivegen Usa Inc.	Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques
WO2016205370A1 (fr)	2015-06-15	2016-12-22	Santa Maria Biotherapeutics, Inc.	Méthodes d'utilisation de protéines à base du récepteur iib de l'activine
US20200231652A1 (en)	2015-08-31	2020-07-23	National Research Council Of Canada	Tgf-b-receptor ectodomain fusion molecules and uses thereof
WO2017177013A1 (fr)	2016-04-06	2017-10-12	Acceleron Pharma Inc.	Antagonistes d'alk7 et leurs utilisations
CA3029890A1 (fr)	2016-07-07	2018-01-11	Acceleron Pharma Inc.	Heteromultimeres de la superfamille tgf-beta et leurs utilisations
WO2018009732A1 (fr)	2016-07-08	2018-01-11	Regeneron Pharmaceuticals, Inc.	Anticorps anti-activine a et méthodes d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire
CA3039573A1 (fr)	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Heteromultimeres alk4:actriib et leurs utilisations
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

2016
- 2016-04-06 MA MA41920A patent/MA41920B1/fr unknown
- 2016-04-06 JP JP2017552155A patent/JP7055636B2/ja not_active Expired - Fee Related
- 2016-04-06 MA MA054328A patent/MA54328A/fr unknown
- 2016-04-06 KR KR1020177031991A patent/KR20180002661A/ko not_active Ceased
- 2016-04-06 CA CA2981833A patent/CA2981833A1/fr active Pending
- 2016-04-06 EA EA202190016A patent/EA202190016A1/ru unknown
- 2016-04-06 EP EP21161146.2A patent/EP3889171B1/fr active Active
- 2016-04-06 EA EA201792222A patent/EA037293B1/ru not_active IP Right Cessation
- 2016-04-06 MA MA053400A patent/MA53400A/fr unknown
- 2016-04-06 HK HK18112314.4A patent/HK1252957A1/zh unknown
- 2016-04-06 KR KR1020177031989A patent/KR20180002659A/ko not_active Ceased
- 2016-04-06 JP JP2017552491A patent/JP7037363B2/ja not_active Expired - Fee Related
- 2016-04-06 EP EP16777003.1A patent/EP3280435B1/fr active Active
- 2016-04-06 US US15/092,577 patent/US10227392B2/en active Active
- 2016-04-06 MX MX2017012846A patent/MX391964B/es unknown
- 2016-04-06 ES ES16777229T patent/ES2863564T3/es active Active
- 2016-04-06 CN CN201680032890.1A patent/CN107847561B/zh not_active Expired - Fee Related
- 2016-04-06 BR BR112017021510A patent/BR112017021510A2/pt not_active IP Right Cessation
- 2016-04-06 WO PCT/US2016/026277 patent/WO2016164503A1/fr not_active Ceased
- 2016-04-06 AU AU2016246708A patent/AU2016246708B2/en not_active Expired - Fee Related
- 2016-04-06 CN CN202210568634.1A patent/CN115073610A/zh active Pending
- 2016-04-06 US US15/092,609 patent/US10227393B2/en active Active
- 2016-04-06 DK DK16777229.2T patent/DK3280728T3/da active
- 2016-04-06 EP EP20206064.6A patent/EP3828199B1/fr active Active
- 2016-04-06 CN CN202210222650.5A patent/CN114736307A/zh active Pending
- 2016-04-06 CN CN201680033093.5A patent/CN107709358A/zh active Pending
- 2016-04-06 EP EP25162196.7A patent/EP4599888A3/fr active Pending
- 2016-04-06 AU AU2016244750A patent/AU2016244750B2/en not_active Ceased
- 2016-04-06 WO PCT/US2016/000033 patent/WO2016164089A2/fr not_active Ceased
- 2016-04-06 CA CA2981737A patent/CA2981737A1/fr active Pending
- 2016-04-06 EP EP16777229.2A patent/EP3280728B1/fr active Active
- 2016-04-06 ES ES20206064T patent/ES3057446T3/es active Active
- 2016-04-06 MA MA041916A patent/MA41916A/fr unknown
- 2016-04-06 HK HK18109788.7A patent/HK1250373A1/zh unknown
2019
- 2019-01-18 US US16/251,935 patent/US11028145B2/en active Active
- 2019-01-18 US US16/251,325 patent/US10906958B2/en active Active
2020
- 2020-11-18 US US16/951,192 patent/US20220396607A1/en not_active Abandoned
- 2020-12-04 AU AU2020281136A patent/AU2020281136A1/en not_active Abandoned
2021
- 2021-01-27 AU AU2021200492A patent/AU2021200492A1/en not_active Abandoned
- 2021-04-15 JP JP2021069060A patent/JP7246618B2/ja active Active
- 2021-04-30 US US17/245,123 patent/US11827689B2/en active Active
2023
- 2023-08-21 US US18/236,082 patent/US20240158468A1/en active Pending

Also Published As

Publication number	Publication date
WO2016164089A3 (fr)	2016-12-08
US11028145B2 (en)	2021-06-08
AU2016244750A1 (en)	2017-10-26
EP3889171A1 (fr)	2021-10-06
HK1250373A1 (zh)	2018-12-14
WO2016164089A2 (fr)	2016-10-13
HK1248735A1 (zh)	2018-10-19
EP3889171B1 (fr)	2025-03-12
EP4599888A3 (fr)	2025-10-29
US20220119491A1 (en)	2022-04-21
US11827689B2 (en)	2023-11-28
EP4599888A2 (fr)	2025-08-13
EP3828199A1 (fr)	2021-06-02
KR20180002659A (ko)	2018-01-08
US10906958B2 (en)	2021-02-02
AU2016246708B2 (en)	2020-12-24
CN107847561A (zh)	2018-03-27
CN107847561B (zh)	2022-03-29
HK1248733A1 (zh)	2018-10-19
EP3280728B1 (fr)	2020-12-16
KR20180002661A (ko)	2018-01-08
EA037293B1 (ru)	2021-03-05
MA41920B1 (fr)	2021-05-31
AU2020281136A1 (en)	2021-01-07
CN114736307A (zh)	2022-07-12
CA2981737A1 (fr)	2016-10-13
MA41916A (fr)	2021-04-14
MX2017012846A (es)	2018-11-09
US20160297867A1 (en)	2016-10-13
DK3280728T3 (da)	2021-03-01
JP2021104057A (ja)	2021-07-26
JP7055636B2 (ja)	2022-04-18
EA202190016A1 (ru)	2021-08-31
JP7037363B2 (ja)	2022-03-16
US20190375820A1 (en)	2019-12-12
EP3280435A4 (fr)	2018-12-19
BR112017021510A2 (pt)	2018-07-03
EP3280728A1 (fr)	2018-02-14
AU2021200492A1 (en)	2021-02-25
US10227392B2 (en)	2019-03-12
EA201792222A1 (ru)	2018-04-30
CA2981833A1 (fr)	2016-10-13
JP2018517399A (ja)	2018-07-05
CN115073610A (zh)	2022-09-20
MA54328A (fr)	2021-10-06
AU2016244750B2 (en)	2021-02-18
AU2016246708A1 (en)	2017-10-26
MX391964B (es)	2025-03-21
US20160298093A1 (en)	2016-10-13
US20220396607A1 (en)	2022-12-15
CN107709358A (zh)	2018-02-16
MA41920A (fr)	2018-02-14
EP3828199B1 (fr)	2025-10-15
US20190225669A1 (en)	2019-07-25
US20240158468A1 (en)	2024-05-16
EP3280435B1 (fr)	2021-06-02
EP3280435A2 (fr)	2018-02-14
ES2863564T3 (es)	2021-10-11
HK1252957A1 (zh)	2019-06-06
JP7246618B2 (ja)	2023-03-28
EP3280728A4 (fr)	2018-09-12
JP2018513147A (ja)	2018-05-24
US10227393B2 (en)	2019-03-12
WO2016164503A1 (fr)	2016-10-13
ES3057446T3 (en)	2026-03-02

Publication	Publication Date	Title
MA53400A (fr)	2021-08-04	Hétéromultimères alk7: actriib et leurs utilisations
FR25C1020I1 (fr)	2025-08-01	Anticorps thérapeutiques et leurs utilisations
MA46472A (fr)	2019-08-14	Hétéromultimères alk4:actriib et leurs utilisations
MA55044A (fr)	2021-12-29	Hétéromultimères alk4:actriib et leurs utilisations
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
EP3600273A4 (fr)	2021-01-20	Inhibiteurs de cd73 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3328895A4 (fr)	2019-08-21	Anticorps anti-pd-l1 et leurs utilisations
EP3471727A4 (fr)	2019-10-09	Inhibiteurs de cxcr4 et leurs utilisations
MA46471A (fr)	2021-05-19	Protéines actriib à variant et leurs utilisations
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3472129A4 (fr)	2019-12-04	Inhibiteurs de cxcr4 et leurs utilisations
MA53184A (fr)	2021-05-26	Anticorps anti-ox40 et leurs utilisations
EP3377102C0 (fr)	2023-08-09	Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3283517A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
EP3356416A4 (fr)	2019-04-10	Anticorps anti-pd-1 et ses utilisations
EP3389658A4 (fr)	2019-07-10	Inhibiteurs de glycosidase et leurs utilisations
EP3334706A4 (fr)	2019-03-13	Pillararènes et utilisations de ceux-ci
EP3349802A4 (fr)	2019-03-20	Dendrimères lipocationiques et leurs utilisations
EP3383904A4 (fr)	2019-12-04	Anticorps ctla-4 et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
EP3624797A4 (fr)	2021-07-21	Inhibiteurs de kinase et leurs utilisations
EP3370528A4 (fr)	2019-05-01	Compositions probiotiques et leurs utilisations
EP3478516A4 (fr)	2020-03-04	Structures multicouches et leurs utilisations
MA43567A (fr)	2018-11-14	Anticorps pacap et leurs utilisations